Rob Lenz
Equibles does not estimate personal net worth.
Get an email with a short summary when Neumora Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get NMRA alertsAbout Rob Lenz
The proxy statement of Neumora Therapeutics, Inc. reports total compensation of $13,582,881 for Rob Lenz in fiscal 2023, including a base salary of $169,231. Neumora Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Neumora Therapeutics, Inc. includes Joshua Pinto (CEO and Board Member), Paul L. Berns (CEO, Chairman and Board Member), Michael Milligan (CFO) and 7 others.
Affiliation history
-
Neumora Therapeutics, Inc. (NMRA)
Source not stated
Current
Company network
Leadership on record at Neumora Therapeutics, Inc.
- Joshua Pinto CEO, Board Member
- Paul L. Berns CEO, Chairman, Board Member
- Michael Milligan CFO
- Bill Aurora COO
- Carol Suh COO
- Jason Duncan General Counsel
- Alaa Halawa Board Member
- David Piacquad Board Member
- Kristina Burow Board Member
- Matthew Fust Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Neumora Therapeutics, Inc. (NMRA) | Head of Research and Development | $169,231 | $13,582,881 |
Recent activity
No call appearances or filed executive changes recorded yet.